Vizionfocus Inc (4771) Fair Value & Analysis
Healthcare · TW · Market cap 11.6B TWD
Fair value as of: Jul 21, 2026
From 17 valuation models · updated 20 days ago
Share price −1.9% over the past month.
Below-average quality, screening 32% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain.
- A fairly wide model range (206.43 TWD to 439.21 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
57‑month range 80.97 TWD – 346.66 TWD · fair‑value band 206.43 TWD – 439.21 TWD · the 209.00 TWD price screens below the 275.23 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Vizionfocus Inc (4771) currently trades at 209.00 TWD, while our model-based Fair Value estimate is 275.23 TWD, implying the stock looks roughly 31.7% undervalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Vizionfocus Inc generated revenue of 3.7B TWD at a net margin of 20.6%. Revenue grew 27.2% year over year. It earns a return on equity of 19.2%. Net debt stands at 597M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 206.43 TWD (bear case) to 439.21 TWD (bull case); at 209.00 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 25% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 32%, 4771 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Growth Earnings (427.67 TWD) versus DCF Models (37.74 TWD). Highest evidence: Residual Income (76).
Notify me when 4771 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 68
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Vizionfocus Inc. engages in the manufacturing of medical equipment in Japan, China, Southeast Asia and the United States. It also manufactures mechanical equipment, optical instruments, and precision instruments; trades internationally; and provides other consulting services.
Full company description
Vizionfocus Inc. engages in the manufacturing of medical equipment in Japan, China, Southeast Asia and the United States. It also manufactures mechanical equipment, optical instruments, and precision instruments; trades internationally; and provides other consulting services. In addition, the company engages in the research and development, design, OEM, development, and sale of contact lenses, as well as customized services. Vizionfocus Inc. was founded in 2012 and is headquartered in Miaoli, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Vizionfocus Inc reported revenue of 3.5B TWD in FY2025 versus 1.4B TWD in FY2021, a compound +25.2%/yr. Reported net income was 808M TWD in FY2025, compounding +36.3%/yr from FY2021.
Watch 4771: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Vizionfocus Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vizionfocus Inc (4771) overvalued or undervalued?
What is the fair value of 4771?
What is the quality score of 4771?
What is the revenue of Vizionfocus Inc (4771)?
What is the net profit margin of 4771?
Does Vizionfocus Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Vizionfocus Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.